142 related articles for article (PubMed ID: 32665993)
21. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
22. The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma.
Dr Hall B; Abel EJ
Urol Clin North Am; 2020 Aug; 47(3):379-388. PubMed ID: 32600539
[TBL] [Abstract][Full Text] [Related]
23. Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Diolombi ML; Cheng L; Argani P; Epstein JI
Am J Surg Pathol; 2015 Dec; 39(12):1621-34. PubMed ID: 26426379
[TBL] [Abstract][Full Text] [Related]
24. Metastasectomy in patients with renal cell carcinoma: when and how?
Omid S; Abufaraj M; Remzi M
Curr Opin Urol; 2020 Jul; 30(4):602-609. PubMed ID: 32464043
[TBL] [Abstract][Full Text] [Related]
25. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Clinicopathologic Analyses of Acquired Cystic Disease-associated Renal Cell Carcinoma With Focus on Adverse Prognostic Factors and Metastatic Lesions.
Kojima F; Gandhi JS; Matsuzaki I; Iba A; Collier S; Yoshikawa T; Kinoshita Y; Warigaya K; Fujimoto M; Kuroda N; Morii E; Hara I; Murata SI; Amin MB
Am J Surg Pathol; 2020 Aug; 44(8):1031-1039. PubMed ID: 32271189
[TBL] [Abstract][Full Text] [Related]
28. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
29. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9.
McKiernan JM; Buttyan R; Bander NH; de la Taille A; Stifelman MD; Emanuel ER; Bagiella E; Rubin MA; Katz AE; Olsson CA; Sawczuk IS
Cancer; 1999 Aug; 86(3):492-7. PubMed ID: 10430258
[TBL] [Abstract][Full Text] [Related]
30. Metastasectomy for Metastatic Renal Cell Carcinoma (mRCC): Lucky Break or Evidence-Based Approach?
Schmidinger M
Ann Surg Oncol; 2017 Feb; 24(2):308-310. PubMed ID: 27671149
[No Abstract] [Full Text] [Related]
31. International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma.
Lyon TD; Roussel E; Sharma V; Carames G; Lohse CM; Costello BA; Boorjian SA; Thompson RH; Joniau S; Albersen M; Leibovich BC
Eur Urol Oncol; 2023 Feb; 6(1):76-83. PubMed ID: 36509653
[TBL] [Abstract][Full Text] [Related]
32. Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser.
Baier B; Kern A; Kaderali L; Bis B; Koschel D; Rolle A
Interact Cardiovasc Thorac Surg; 2015 Aug; 21(2):211-7. PubMed ID: 25977131
[TBL] [Abstract][Full Text] [Related]
33. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical profile of renal cell tumours].
Gutiérrez Olivares VM; González Torres LM; Hunter Cuartas G; Niebles De la Hoz MC
Rev Esp Patol; 2019; 52(4):214-221. PubMed ID: 31530404
[TBL] [Abstract][Full Text] [Related]
35. VEGF receptor subtypes may serve as novel prognostic factors and putative indicators for anti VEGF receptor treatment response in renal cell carcinoma cases.
Eronat O; Onursever A; Suren D; Yildirim M; Kandemir O; Ali Kahya H
J BUON; 2016; 21(5):1250-1258. PubMed ID: 27837630
[TBL] [Abstract][Full Text] [Related]
36. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.
Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L
Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955
[TBL] [Abstract][Full Text] [Related]
37. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
38. Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review.
Tayeh GA; Alkassis M; De La Taille A; Vordos D; Champy CM; Pelegrin T; Ingels A
World J Urol; 2024 Jan; 42(1):51. PubMed ID: 38244094
[TBL] [Abstract][Full Text] [Related]
39. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
[TBL] [Abstract][Full Text] [Related]
40. Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.
Osman WM; Youssef NS
Int J Clin Exp Pathol; 2015; 8(7):8165-77. PubMed ID: 26339385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
